Condition: Stroke, Ischemic · Stroke, Acute · Thrombosis, Brain · Sponsor: Xuanwu Hospital, Beijing
A phase III, multicentre, prospective, randomised, open-label, blinded-endpoint clinical trial will evaluate two thrombolytic agents for the treatment of acute large vessel occlusion stroke within 4.5 hours from symptoms onset: intravenous tenecteplase bridging mechanical thrombectomy vs. intravenous alteplase bridging mechanical thrombectomy.
This description comes directly from the study's public registry record.
Lu Wang, MD · 13161090533 · wanglu3261999@163.com
Xiuhai Guo, MD · 18810285127 · guoxhxuan@126.com
Always discuss trial participation with your own doctor first.
| Xuanwu Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06658197